Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Joe O’Sullivan, MD, FRCR, FFRRCSI, FRCPI, of Queen’s University Belfast, Belfast, UK, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, and explains the promising safety results of the AdRad trial that investigated the combination of radium-223 and VMAT radiotherapy in patients presenting with metastatic prostate cancer (NCT00653848).
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.